Genetic Testing Market by Type (Predictive & Presymptomatic Testing, Prenatal & Newborn Testing, Carrier Testing, Diagnostic Testing, Pharmacogenomic Testing, Others) by Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), by Application (Cancer Diagnosis, Cardiovascular Disease Diagnosis, Genetic Disease Diagnosis, Other), by Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Global Forecasts 2021 To 2027

Market Overview:

The Global Genetic Testing Market was valued at US$ 11,701.8 Mn in 2020 is expected to reach US$ 24,194.7 Mn by 2027, with a growing CAGR of 10.2% during the forecast period (2021-2027).

Genetic testing is a technique used to examine DNA or RNA. This technique helps to understand the changes occurring in genes or to analyse the core of genetic disorder or disease. Genetic testing provides important information related to mutations and help to prevent or diagnose illness. For instance, genetic testing can be used to confirm or identify cystic fibrosis or Huntington disease.

Genetic Testing Market

Introduction of innovative technologies and procedures for genetic testing provides refined results with accuracy and efficiency prove to have high impact on the market. Accessibility of effective and sensitive procedures for genetic therapy for new born or prenatal testing offers new approach for initial screening during pregnancy. Other factors such as adoption of innovative diagnosis procedures, involvement of government initiatives and funding, awareness regarding successful genetic therapies and increase in number of players in the market drives the growth of genetic testing market. However, high treatment cost may hamper the overall sales of the market.

Genetic Testing Segmentation:

By Type

  • Predictive & Presymptomatic Testing
  •  Prenatal & Newborn Testing
  •  Carrier Testing
  • Diagnostic Testing
  •  Pharmacogenomic Testing
  •  Other

By Technology

  • Cytogenetic Testing
  • Biochemical Testing
  • Molecular Testing

By Applications

  • Cancer Diagnosis
  • Cardiovascular Disease Diagnosis
  • Genetic Disease Diagnosis
  • Other

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Based on type, prenatal & new born testing segment dominated market in 2020 and expected to maintain the same during the forecast period.

Based on type, genetic testing is broadly segmented into predictive & Presymptomatic Testing, Prenatal & Newborn Testing, Carrier Testing, Diagnostic Testing and Pharmacogenomic Testing. Prenatal and new born testing segment is expected to dominate the market during forecast period. This segment is expected to hold highest market revenue in coming years. This is due to increase in awareness and concern among population regarding prenatal screening and it’s benefits and increase in incidence of mortality in genetic diseases across globe.  On the other hand, pharmacogenomics segment is expected to have the highest CAGR during the forecast period. This type of testing helps to detect and diagnose genetic abnormalities during pregnancy or child birth. This type of genetic testing also helps to point out birth defects or syndromes associated with genes.

Based on technology, molecular testing segment held the highest market share in genetic testing market in 2020 and is expected to expand more during the forecast period.

Based on technology, genetic testing market is broadly segmented into Biochemical Testing, Cytogenetic Testing, and Molecular Testing. Molecular testing held the maximum market share in 2020 and expected to increase more during the forecast period. The growth of this segment attributes the fact that there is increase in use of molecular technology usage in diagnosis and treating diseases. Complications at molecular level can be identified and diagnosed using this technology.  This technique is highly used in analysing the losses and gain in DNA that cannot be detected in manual techniques. This factor drives the growth of segment in genetic testing market.

Based on application, cancer diagnosis hold eminent position in the market with high market share

On the basis of application, genetic testing market is segmented into Cancer Diagnosis, Cardiovascular Disease Diagnosis and Genetic Disease Diagnosis. Cancer segment held the maximum share of genetic testing market in 2020. This is due to increase in number of cancer patients due to unhealthy diet, adoption of western life style, and increase in consumption of alcohol and smoking led to cause cancer. 

Based on geographical region, North America had dominance in 2020 in the market and expected to do same during the forecast period.

Geographically, North America captured the largest market share in 2020 and expected to maintain its dominance during forecast period. This is due to presence of key players in this region, presence of developed healthcare and research infrastructure in this region, growing government initiatives and increasing mergers and acquisitions in this region drives the growth of genetic testing market.

However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period due to ongoing development in technology in countries like India and China, increased in awareness regarding early genetic screening followed by surge in healthcare expenditure drives the growth in this region.

The report also provides in-depth analysis of genetic testing dynamics such as drivers, restraints opportunities and challenges


  • Increase in Adoption of Advanced testing tools in Healthcare
  • Growing Government Funding and Initiatives in Technology in Healthcare Industry
  • Increase in Incidence of Diseases Such as Cancer and Genetic Predisposition
  • Rise in Use of Genetic Testing in Pharmacogenomics


  • Stringent Regulatory Guidelines and Policies for Product Approval
  • Concerns Related to Standardization of Genetic Testing-Based Diagnosis


  • Exploring Untapped Market in Developing Countries Like India, China, and Mexico Provides Opportunity for the Market Players
  • Upcoming Development in Genetic Therapy

COVID-19 Impact on the Genetic Testing Market Analysis

Covid-19 has highly affected the industries in terms of growth, economy, health and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety. Genetic testing market has been adversely affected by Covid-19 outbreak. Genetic counsellor and doctors were unable to check patients face to face due to social distancing. Availability of doctors and labs were limited. Priority was given to the coronavirus infected patients for the treatments. Government implemented guidelines for lockdown and restrictions on movement within region or outside. However, genetic testing giant companies and labs were given a choice where they can deliver clinician ordered test. Virtual counselling was adopted during pandemic using telehealth. However, prenatal and genetic disorder testing was least affected. Counselling for prenatal and new born genetic testing was allowed in global pandemic.

The report also provides in-depth analysis of key trends in genetic testing marke

Sr. No.




Covid –19 had badly impacted genetic testing market, since, doctors and Counsellors were unable to check patients physically 



Increase in government initiatives, new innovative testing techniques and awareness & adoption of genetic treatment 



Supportive reimbursement scenario in the US and many developed countries 



High cost for Testing  


The report also provides in-depth analysis of recent news developments and investments

  • In June 2021, Eurofins Scientific signed an agreement to acquire DNA diagnostics Center in order to expand their services of DNA testing and support personalized lifestyle and health awareness. This will also help to expand Eurofins market.
  • In May 2021, PerfinElmer signed an agreement to acquire IDS at $155 Million. After this acquisition, PerfinElmer will be able to expand their business in diagnostics and immunodiagnostics segment.

Genetic Testing Market Company Profiles and Competitive Intelligence

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Eurofins Scientific
  • Illumina, Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • CSL Ltd.
  • Agilent Technologies Inc.
  • Natera Inc.
  • Cepheid
  • ELITech Group
  • Autogenomics

The unique insights provided by this report also includes the following:

  • In-depth value chain analysis
  • Opportunity mapping
  • Sector snapshot
  • Key Players Positioning Matrix
  • Regulatory scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market trends
  • Covid-19 impact analysis
  • Product comparison
  • Pre & Post COVID 19 impacts on Genetic Testing
  • Competitive Landscape

Frequently Asked Questions (FAQs)

The global genetic testing market was valued at USD 11,701.8 Mn in 2020 and is anticipated to reach US$ 24,194.7 Mn by 2027.

The genetic testing market is estimated to grow at a compound annual growth rate (CAGR) of 10.2% during 2021-2027.

In the base year 2020, North America accounted for about 40% share in the genetic testing market.

Few key players include, but not limit up to: Abbott Laboratories, Eurofins Scientific, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Illumina, Inc., Danaher Corporation, CSL Ltd, F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific, Inc.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

Table of Contents Genetic Testing Market:

    1. Product Outline
    2. What is Genetic Testing
    3. Analysis of Genetic Testing
    4. Covid -19 Impact
    5. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
    6. Technology Overview
  2. Regulatory Landscape for Genetic Testing
    1. Regulations and Standards
  3. Genetic Testing Market by Type
    1. Predictive & Presymptomatic Testing
    2. Prenatal & Newborn Testing
    3. Carrier Testing
    4. Diagnostic Testing
    5. Pharmacogenomic Testing
    6. Other
  4. Genetic Testing Market by Technology
    1. Cytogenetic Testing
    2. Biochemical Testing
    3. Molecular Testing
  5. Genetic Testing Market by Application
    1. Cancer Diagnosis
    2. Cardiovascular Disease Diagnosis
    3. Genetic Disease Diagnosis
    4. Other
  6. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Netherlands
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Latin America
    5. Middle East & Africa
  7. Key Strategic Insights
  8. New Raw Material Sources
    1. New Applications
    2. Emerging Technologies
    3. Opportunity Mapping
    4. Critical Success Factors
    5. Consumer Preferences
  9. Key Market Trends / Recent Developments
  10. Competitive Scenario
    1. Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product launches
    5. Ranking of Key Players
  11. Key Global Players
    1. Abbott Laboratories
    2. Bio-Rad Laboratories, Inc.
    3. Myriad Genetics, Inc.
    4. Danaher Corporation
    5. F. Hoffmann-La Roche Ltd.
    6. Eurofins Scientific
    7. Illumina, Inc.
    8. Qiagen N.V.
    9. Thermo Fisher Scientific, Inc.
    10. CSL Ltd.
    11. Agilent Technologies Inc.

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization